U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process (Drugs)
  4. CDER Small Business & Industry Assistance (SBIA)
  5. CDER Small Business and Industry Assistance (CDER SBIA) Webinar - Draft Guidance for Industry: Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA
  1. Development & Approval Process (Drugs)

CDER Small Business and Industry Assistance (CDER SBIA) Webinar - Draft Guidance for Industry: Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA

CDER Small Business and Industry Assistance (CDER SBIA) Webinar - Draft Guidance for Industry: Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA

SBIA Webinar 2016

 

The Food and Drug Administration, Center for Drug Evaluation and Research and Small Business and Industry Assistance (CDER SBIA), invites you to our webinar series.

These events focus on a specific topic and provide an opportunity for small business and industry entities to learn more about the FDA and basic drug regulation. The webinars support CDER SBIA’s mission of promoting productive interaction with regulated industry by assisting small pharmaceutical business and industry with information relating to the development and regulation of human drug products.

On 10/2/2017, the FDA issued the Draft Guidance for Industry: Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA.

This draft guidance describes the enhanced process for discussions between FDA and a prospective applicant preparing to submit (or an applicant that has submitted) an Abbreviated New Drug Application (ANDA) for a complex generic drug product to FDA. The guidance provides information on requesting and conducting product development meetings, pre-submission meetings, and mid-review-cycle meetings with FDA.

FDA is issuing this webinar to assist ANDA applicants and prospective applicants in creating and submitting meeting requests, including meeting package materials, for formal meetings with FDA regarding complex generic drug products as defined in the Generic Drug User Fee Amendments Reauthorization (GDUFA II) Performance Goals and Program Enhancements Fiscal Years 2018-2022 (GDUFA II Goals or Commitment Letter).

Featured Speaker:
Elizabeth Giaquinto Friedman, JD, LLM
Regulatory Counsel
Office of Generic Drugs
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

 


For questions concerning the webinar, please contact CDER SBIA at:
(866) 405-5367 | (301) 796-6707

 

If you've never used Connect Pro, get a quick overview: http://www.adobe.com/go/connectpro_overview

Test your connection: https://collaboration.fda.gov/common/help/en/support/meeting_test.htm

Adobe, the Adobe logo, Acrobat and Acrobat Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.

 

Resources for You